These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

478 related articles for article (PubMed ID: 25918406)

  • 1. Cas9-mediated targeting of viral RNA in eukaryotic cells.
    Price AA; Sampson TR; Ratner HK; Grakoui A; Weiss DS
    Proc Natl Acad Sci U S A; 2015 May; 112(19):6164-9. PubMed ID: 25918406
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Francisella novicida CRISPR-Cas Systems Can Functionally Complement Each Other in DNA Defense while Providing Target Flexibility.
    Ratner HK; Weiss DS
    J Bacteriol; 2020 May; 202(12):. PubMed ID: 32284320
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting hepatitis B virus cccDNA by CRISPR/Cas9 nuclease efficiently inhibits viral replication.
    Dong C; Qu L; Wang H; Wei L; Dong Y; Xiong S
    Antiviral Res; 2015 Jun; 118():110-7. PubMed ID: 25843425
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Programmable DNA cleavage in vitro by Cas9.
    Karvelis T; Gasiunas G; Siksnys V
    Biochem Soc Trans; 2013 Dec; 41(6):1401-6. PubMed ID: 24256227
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bacterial CRISPR/Cas DNA endonucleases: A revolutionary technology that could dramatically impact viral research and treatment.
    Kennedy EM; Cullen BR
    Virology; 2015 May; 479-480():213-20. PubMed ID: 25759096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cas9-dependent endogenous gene regulation is required for bacterial virulence.
    Sampson TR; Weiss DS
    Biochem Soc Trans; 2013 Dec; 41(6):1407-11. PubMed ID: 24256228
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cas9 specifies functional viral targets during CRISPR-Cas adaptation.
    Heler R; Samai P; Modell JW; Weiner C; Goldberg GW; Bikard D; Marraffini LA
    Nature; 2015 Mar; 519(7542):199-202. PubMed ID: 25707807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure and Engineering of Francisella novicida Cas9.
    Hirano H; Gootenberg JS; Horii T; Abudayyeh OO; Kimura M; Hsu PD; Nakane T; Ishitani R; Hatada I; Zhang F; Nishimasu H; Nureki O
    Cell; 2016 Feb; 164(5):950-61. PubMed ID: 26875867
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Genome engineering using CRISPR-Cas9 system.
    Cong L; Zhang F
    Methods Mol Biol; 2015; 1239():197-217. PubMed ID: 25408407
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nucleosomes Inhibit Cas9 Endonuclease Activity in Vitro.
    Hinz JM; Laughery MF; Wyrick JJ
    Biochemistry; 2015 Dec; 54(48):7063-6. PubMed ID: 26579937
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assembly of Francisella novicida Cpf1 endonuclease in complex with guide RNA and target DNA.
    Alcón P; Montoya G; Stella S
    Acta Crystallogr F Struct Biol Commun; 2017 Jul; 73(Pt 7):409-415. PubMed ID: 28695850
    [TBL] [Abstract][Full Text] [Related]  

  • 12. crRNA complementarity shifts endogenous CRISPR-Cas systems between transcriptional repression and DNA defense.
    Ratner HK; Weiss DS
    RNA Biol; 2021 Nov; 18(11):1560-1573. PubMed ID: 33733999
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Conservation and variability in the structure and function of the Cas5d endoribonuclease in the CRISPR-mediated microbial immune system.
    Koo Y; Ka D; Kim EJ; Suh N; Bae E
    J Mol Biol; 2013 Oct; 425(20):3799-810. PubMed ID: 23500492
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Application of CRISPR/Cas9 genome editing to the study and treatment of disease.
    Pellagatti A; Dolatshad H; Valletta S; Boultwood J
    Arch Toxicol; 2015 Jul; 89(7):1023-34. PubMed ID: 25827103
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Suppression of hepatitis B virus DNA accumulation in chronically infected cells using a bacterial CRISPR/Cas RNA-guided DNA endonuclease.
    Kennedy EM; Bassit LC; Mueller H; Kornepati AVR; Bogerd HP; Nie T; Chatterjee P; Javanbakht H; Schinazi RF; Cullen BR
    Virology; 2015 Feb; 476():196-205. PubMed ID: 25553515
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dynamics of CRISPR-Cas9 genome interrogation in living cells.
    Knight SC; Xie L; Deng W; Guglielmi B; Witkowsky LB; Bosanac L; Zhang ET; El Beheiry M; Masson JB; Dahan M; Liu Z; Doudna JA; Tjian R
    Science; 2015 Nov; 350(6262):823-6. PubMed ID: 26564855
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR-Cas13a mediated targeting of hepatitis C virus internal-ribosomal entry site (IRES) as an effective antiviral strategy.
    Ashraf MU; Salman HM; Khalid MF; Khan MHF; Anwar S; Afzal S; Idrees M; Chaudhary SU
    Biomed Pharmacother; 2021 Apr; 136():111239. PubMed ID: 33454599
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutting it close: CRISPR-associated endoribonuclease structure and function.
    Hochstrasser ML; Doudna JA
    Trends Biochem Sci; 2015 Jan; 40(1):58-66. PubMed ID: 25468820
    [TBL] [Abstract][Full Text] [Related]  

  • 19. RNA-Independent DNA Cleavage Activities of Cas9 and Cas12a.
    Sundaresan R; Parameshwaran HP; Yogesha SD; Keilbarth MW; Rajan R
    Cell Rep; 2017 Dec; 21(13):3728-3739. PubMed ID: 29281823
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cas9-crRNA ribonucleoprotein complex mediates specific DNA cleavage for adaptive immunity in bacteria.
    Gasiunas G; Barrangou R; Horvath P; Siksnys V
    Proc Natl Acad Sci U S A; 2012 Sep; 109(39):E2579-86. PubMed ID: 22949671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.